Description
HRSV (B) Post-fusion glycoprotein F0, His Tag (MALS verified) | RSF-V52H9-50ug| Gentaur Distribution US, UK & Europe
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.
Source: HRSV (B) Post-fusion glycoprotein F0, His Tag (RSF-V52H9) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Asn 524 (Accession # O36634).
Format: Powder.
Tag: C-10×His.
Expression System: HEK293.
Expression Region: Gln 26 - Asn 524.
Conjugate: Unconjugated.
Molecular Weight: 55.2 kDa.
Characteristics: This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 55.2 kDa. The protein migrates as 16-18 kDa and 43-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity: 90%.
Buffer: PBS.
Storage Conditions: -20℃.
Shipping Conditions: RT
